This is a news story, published by Ars Technica, that relates primarily to DEA news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Adderall shortage. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Adderall news, amphetamine products news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Vyvanse shortageArs Technica
•87% Informative
The DEA says it will increase the allowed production amount of lisdexamfetamine by roughly 23.5 percent .
This week , the DEA also allowed for a corresponding increase in d-amphetamine, which is needed for production.
The FDA and DEA said they would work with manufacturers to ensure they would ramp up production of drugs in short supply.
VR Score
87
Informative language
86
Neutral language
64
Article tone
formal
Language
English
Language complexity
66
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
9
Source diversity
7
Affiliate links
no affiliate links